favorites

Novo Nordisk’s Wegovy sales jump on international rollouts

Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.

Naomi Kresge

Patients on semaglutide were less than half as likely to overdose as those on insulin.

Positive results in the early stages of Roche's weight-loss pill development had given investors hope it could quickly catch up with rivals Novo...

Positive results in the earliest stages of development have driven about $93 billion in market value gains this year for obesity-drug makers.